Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.
- NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.
- NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_assertion evidence source_evidence_literature NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.
- NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_assertion SIO_000772 23307549 NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.
- NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_assertion wasDerivedFrom befree-2016 NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.
- NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_assertion wasGeneratedBy ECO_0000203 NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.
- befree-2016 importedOn "2016-02-19" NP1042712.RAHj5sxy_Wyr6nZcf_B7lsTayZ8foQpAgWEqN8F2ox7q8130_provenance.